Merck sign multi-year partnership with cloud platform Saama

Data analytics firm Saama Technologies recently announced a new agreement with biopharmaceutical multinational Merck in a bid to create a new clinical data management system. Using the Saama Life Science Analytics Cloud (LSAC) as the base for the new system, the platform will benefit researchers by organising a broad range of clinical data in a single, user-friendly environment.

During the process of developing new therapies and pharmaceuticals, countless data points are created that could be extremely valuable if they are analysed correctly. Embracing data analytics can not only speed up the development process but also unlock insights into novel drugs and help ensure the most effective drug is developed.

Once this has been achieved, it will be far easier for data to be monitored and analysed between clinical collaborators. As part of the partnership both Merck and Saama will work together to incorporate the AI-backed LASC technologies into Merck’s clinical systems.

According to Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories, this integration will help realise efficiencies and improve the overall experience for all clinical teams.

“With the increasing demands of Merck’s growing pipeline, it is crucial that we continue to embrace the latest digital technologies to optimize and expedite our data management, clinical trial operations and biostatistics capabilities,” said Barr.

Merck will be joining other leading businesses in the pharmaceutical space who make use of solutions offered by Saama, with more than 50 biotech firms using the LASC platform to support research development. Backed by AI and machine learning tools that have been extensively trained with over a 100 million clinical data points, powerful data aggregation abilities can be unlocked thanks to this partnership.